Eli Lilly (NYSE: LLY) has announced plans to enhance its existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.
The US pharma major says it has reached an agreement to acquire CoLucid Pharmaceuticals (Nasdaq: CLCD) for $46.50 per share - a 33% premium to the stock’s closing price on Tuesday - or around $960 million. CoLucid shares leapt 32.7% to $46.30 in pre-market trading today.
The transaction is expected to close by the end of the first quarter of 2017, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze